866-997-4948(US-Canada Toll Free)

Alpha 1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 153 Pages

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Overview

Alpha-1 Antitrypsin also referred as AAT, is a type of protein belongs to the class protease inhibitor. This protein is produced in the liver and is primarily functions to protect the lungs and liver from the harmful effects of other protein in the body. The AAT deficiency is genetic disorder that causes low and defective production of AAT proteins in liver which results in the accumulation of AAT in the liver and low amount of it in blood stream. The presence of AAT deficiency can be diagnosed using blood test, genetic tests and biopsy tests. Patients with severe AAT deficiency get affected by liver cirrhosis, chronic obstructive pulmonary diseases (COPD), and emphysema diseases. The diagnosis rate for alpha-1 antitrypsin deficiency across the globe is one of the crucial indicators of the alpha-1 antitrypsin deficiency treatment market. The AAT deficiency disease can be treated using different therapeutic methods such as augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and other treatment methods.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Trends and Opportunities

The worldwide increase in the incidences and prevalence of respiratory diseases is projected to be key driving factor for the global AAT deficiency market during forecast period. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is likely to be the fourth leading cause of death in the world by 2030, while asthma affects about 235 million people globally. AAT deficiency is most commonly observed in the North America and European countries which is likely to drive the market. The increasing awareness about AAT deficiency disorder in developed countries, technological development in in the production and purification of Alpha-1 Antitrypsin protein, and government initiatives for increasing blood and plasma derived products would boost the growth of global AAT deficiency treatment market. The AAT deficiency is common, but under diagnosed condition in most of countries. The slow diagnosis rates of AAT deficiency and high cost of treatment is likely to hamper growth of global AAT deficiency treatment market over forecast period. Alpha-1 antitrypsin deficiency (A1AD) mostly occurs in the Caucasian population of European descent, affecting approximately 100,000 Americans. However, most cases of A1AD are undetected, making alpha-1 antitrypsin deficiency a highly under-diagnosed disorder. Also the treatment of AAT deficiency may lead to development of several chronic side effects such as back/joint pain, chest pain, musculoskeletal pain, rhinorrhea, sinusitis, fever, nausea, or shortness of breath, peripheral edema, and urticarial. These side effects can sometimes force a patient to discontinue the therapy as alpha-1 antitrypsin is a natural enzyme inhibitor product.

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Geographical Segmentation

Geographically, the global AAT deficiency treatment market has been segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America dominated the global AAT deficiency treatment market in 2016 and is likely to lose its market share to Europe by the end of 2025.  Europe is projected to expand at highest CAGR during forecast period and is likely to gain its market share by the end of 2025. All the regions have been further segmented by countries, product type, by material and End-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global AAT deficiency treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the non-vascular stents market, and profiled in the report include Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC, Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Treatment Type

  • Augmentation Therapy
  • Aralast
  • Prolastin
  • Zemaira/Respreeza
  • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Table of Content

Chapter 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

Chapter 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

Chapter 3. Executive Summary: 
3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot 
3.2. Market Share Analysis by Region, 2016

Chapter 4. Market Overview
4.1. Market Overview
4.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Indicators
4.3. Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
4.4. Global Alpha-1 Antitrypsin Deficiency Treatment Market : Market Outlook

Chapter 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increase in prevalence and incidence of respiratory diseases
5.2.2. Improved technology for production and purification methods
5.2.3. Rise in prescription of combination therapies
5.2.4. High R&D in asthma and COPD treatment
5.2.5. Increasing awareness programs
5.2.6. Favorable government initiatives and approvals
5.2.7. Rise in health care spending and improvement health care infrastructure
5.2.8. Development of better diagnostic methods
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Demand-supply gap
5.3.4. Limitation regarding reliable clinical data
5.3.5. Low diagnosis rate
5.4. Opportunities
5.4.1. Alternative potential therapies
5.4.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.5. Key Trends
5.6. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis
5.7. Comparative Brand Analysis
5.8. Porter’s Five Forces Analysis 
5.9. Epidemiology: Alpha-1 Antitrypsin Deficiency
5.10. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
5.11. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

Chapter 6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment
6.1. Introduction 
6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment
6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment
6.3.1. Augmentation Therapy
6.3.1.1. Aralast
6.3.1.2. Prolastin
6.3.1.3. Zemaira/Respreeza
6.3.1.4. Glassia
6.3.2. Bronchodilator
6.3.3. Corticosteroids
6.3.4. Oxygen Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment

Chapter 7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user
7.1. Introduction 
7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User
7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user
7.3.1. Specialty Clinics
7.3.2. Hospitals
7.3.3. Pharmacies 
7.4. Market Attractiveness, by End-User

Chapter 8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration
8.1. Introduction 
8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration
8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration 
8.2.2. Parenteral
8.2.3. Inhalation
8.2.4. Oral
8.3. Market Attractiveness by Route of Administration

Chapter 9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region
9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook
9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region
9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region
9.4. Market Attractiveness Analysis, by Region

Chapter 10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
10.1. Market Overview
10.2. Market Analysis, by Treatment
10.2.1. Market Value Share Analysis, by Treatment
10.2.2. Market Size (US$ Mn) Forecast, by Treatment
10.2.2.1. Augmentation Therapy
10.2.2.1.1. Aralast
10.2.2.1.2. Prolastin
10.2.2.1.3. Zemaira/Respreeza
10.2.2.1.4. Glassia
10.2.2.2. Bronchodilator
10.2.2.3. Corticosteroids
10.2.2.4. Oxygen Therapy
10.2.2.5. Others
10.3. Market size (US$ Mn), by End-user
10.3.1. Market Value Share Analysis, by End-user
10.3.2. Market Size (US$ Mn) Forecast, by End-user
10.3.2.1. Specialty Clinics
10.3.2.2. Hospitals
10.3.2.3. Pharmacies
10.4. Market size (US$ Mn) Forecast, by Country
10.4.1. Market Value Share Analysis, by Country
10.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
10.4.2.1. U.S.
10.4.2.2. Canada
10.5. Market Attractiveness Analysis 
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country

Chapter 11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
11.1. Market Overview
11.2. Market Analysis, by Treatment
11.2.1. Market Value Share Analysis, by Treatment
11.2.2. Market Size (US$ Mn) Forecast, by Treatment
11.2.2.1. Augmentation Therapy
11.2.2.1.1. Aralast
11.2.2.1.2. Prolastin
11.2.2.1.3. Zemaira/Respreeza
11.2.2.1.4. Glassia
11.2.2.2. Bronchodilator
11.2.2.3. Corticosteroids
11.2.2.4. Oxygen Therapy
11.2.2.5. Others
11.3. Market size (US$ Mn), by End-user
11.3.1. Market Value Share Analysis, by End-user
11.3.2. Market Size (US$ Mn) Forecast, by End-user
11.3.2.1. Specialty Clinics
11.3.2.2. Hospitals
11.3.2.3. Pharmacies
11.4. Market size (US$ Mn) Forecast, by Country
11.4.1. Market Value Share Analysis, by Country
11.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
11.4.2.1. U.K.
11.4.2.2. Germany
11.4.2.3. France 
11.4.2.4. Italy
11.4.2.5. Spain
11.4.2.6. Rest of Europe
11.5. Market Attractiveness Analysis 
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country

Chapter 12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
12.1. Market Overview
12.2. Market Analysis, by Treatment
12.2.1. Market Value Share Analysis, by Treatment
12.2.2. Market Size (US$ Mn) Forecast, by Treatment
12.2.2.1. Augmentation Therapy
12.2.2.1.1. Aralast
12.2.2.1.2. Prolastin
12.2.2.1.3. Zemaira/Respreeza
12.2.2.1.4. Glassia
12.2.2.2. Bronchodilator
12.2.2.3. Corticosteroids
12.2.2.4. Oxygen Therapy
12.2.2.5. Others
12.3. Market size (US$ Mn), by End-user
12.3.1. Market Value Share Analysis, by End-user
12.3.2. Market Size (US$ Mn) Forecast, by End-user
12.3.2.1. Specialty Clinics
12.3.2.2. Hospitals
12.3.2.3. Pharmacies
12.4. Market size (US$ Mn) Forecast, by Country
12.4.1. Market Value Share Analysis, by Country
12.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
12.4.2.1. Australia
12.4.2.2. Rest of Asia Pacific
12.5. Market Attractiveness Analysis 
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country

Chapter 13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
13.1. Market Overview
13.2. Market Analysis, by Treatment
13.2.1. Market Value Share Analysis, by Treatment
13.2.2. Market Size (US$ Mn) Forecast, by Treatment
13.2.2.1. Augmentation Therapy
13.2.2.1.1. Aralast
13.2.2.1.2. Prolastin
13.2.2.1.3. Zemaira/Respreeza
13.2.2.1.4. Glassia
13.2.2.2. Bronchodilator
13.2.2.3. Corticosteroids
13.2.2.4. Oxygen Therapy
13.2.2.5. Others
13.3. Market size (US$ Mn), by End-user
13.3.1. Market Value Share Analysis, by End-user
13.3.2. Market Size (US$ Mn) Forecast, by End-user
13.3.2.1. Specialty Clinics
13.3.2.2. Hospitals
13.3.2.3. Pharmacies
13.4. Market size (US$ Mn) Forecast, by Country
13.4.1. Market Value Share Analysis, by Country
13.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
13.4.2.1. Brazil
13.4.2.2. Mexico
13.4.2.3. Rest of LATAM
13.5. Market Attractiveness Analysis 
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country

Chapter 14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
14.1. Market Overview
14.2. Market Analysis, by Treatment
14.2.1. Market Value Share Analysis, by Treatment
14.2.2. Market Size (US$ Mn) Forecast, by Treatment
14.2.2.1. Augmentation Therapy
14.2.2.1.1. Aralast
14.2.2.1.2. Prolastin
14.2.2.1.3. Zemaira/Respreeza
14.2.2.1.4. Glassia
14.2.2.2. Bronchodilator
14.2.2.3. Corticosteroids
14.2.2.4. Oxygen Therapy
14.2.2.5. Others
14.3. Market size (US$ Mn), by End-user
14.3.1. Market Value Share Analysis, by End-user
14.3.2. Market Size (US$ Mn) Forecast, by End-user
14.3.2.1. Specialty Clinics
14.3.2.2. Hospitals
14.3.2.3. Pharmacies
14.4. Market size (US$ Mn) Forecast, by Country
14.4.1. Market Value Share Analysis, by Country
14.4.2. Market Size (US$ Mn) Forecast, by Country, 2017–2025
14.4.2.1. South Africa
14.4.2.2. Saudi Arabia
14.4.2.3. Rest of MEA
14.5. Market Attractiveness Analysis 
14.5.1. By Treatment
14.5.2. By End-user
14.5.3. By Country

Chapter 15. Competition Landscape
15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
15.2. Company Profiles
15.2.1. Grifols, S.A.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. AstraZeneca
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Teva Pharmaceutical Industries Ltd.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Boehringer Ingelheim GmbH
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. GlaxoSmithKline Plc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.6. CSL Behring LLC
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. Shire plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Pfizer Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. LFB Biomedicaments S.A.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
15.2.10. Kamada Ltd
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. SWOT Analysis
15.2.10.4. Strategic Overview

List of Table

Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands
Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2025
Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2025
Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 11: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 14: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
Table 15: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025 
Table 16: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 18: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 19: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 20: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2015–2025
Table 21: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 22: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025

List of Chart

Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot
Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 03: Market Value Share By Treatment Type (2016)
Figure 04: Market Value Share By End-user (2016)
Figure 05: Market Value Share By Region(2016)
Figure 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2015–2025
Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2015–2025
Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2015–2025
Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 12: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 13: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 14: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2015–2025
Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2015–2025
Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 23: Global Parenteral Market Revenue, US$ Mn,
Figure 24: Global Inhalation Market Revenue, US$ Mn,
Figure 25: Global Oral Market Revenue, US$ Mn, 2015–2025
Figure 26: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration
Figure 27: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2016 and 2025
Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region
Figure 29: North America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 30: North America Market Attractiveness Analysis, by Country
Figure 31: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 36: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2017–2025
Figure 37: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 38: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 43: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 44: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 45: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 46: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 47: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 50: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 51: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country
Figure 52: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 53: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2016 and 2025
Figure 54: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 55: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment
Figure 56: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user
Figure 57: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 59: Middle East & Africa Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 60: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2025
Figure 61: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2025
Figure 62: Middle East & Africa Market Attractiveness Analysis, by Treatment
Figure 63: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 64: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
Figure 65: Grifols, S.A. Breakdown of Net Sales, by Region, 2016
Figure 66: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2016
Figure 68: AstraZeneca Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 69: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2016
Figure 70: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 71: Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (2016)
Figure 72: Boehringer Ingelheim GmbH Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 73: GlaxoSmithKline Plc. Breakdown of Net Sales, by Region, 2016
Figure 74: GlaxoSmithKline Plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 75: CSL Behring LLC Breakdown of Net Sales, by Region, 2016
Figure 76: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 77: Shire plc Breakdown of Net Sales, by Segment, 2016
Figure 78: Shire plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 79: Pfizer Inc. Breakdown of Net Sales, by Region, 2016
Figure 80: Pfizer Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 81: LFB Biomedicaments S.A. Breakdown of Net Sales, by Region, 2015
Figure 82: LFB Biomedicaments S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2012–2015
Figure 83: Kamada Ltd. Breakdown of Net Sales (2016), by Segments
Figure 84: Kamada Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *